Kami Maddocks, MD, Ohio State University Medical Center

Articles by Kami Maddocks, MD, Ohio State University Medical Center

Closing Thoughts on Treatment of R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

Improving Outcomes in Patients With R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

Emerging Therapies for R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

Safety and Efficacy of Oral Agents in R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

Treatment of R/R DLBCL: CD19-Directed Therapy vs CAR T

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

CD19-Directed Therapies for Treatment of R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

CAR T in R/R DLBCL: Safety and Patient Selection

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

ASCO 2020 Data: CAR T in R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

Role of CAR T-cell Therapy in R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

Treatment in Transplant-ineligible R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

Prognosis of R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

Standard of Care for Treatment of DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

Latest Updated Articles

Safety and Efficacy of Oral Agents in R/R DLBCL
July 15th 2020
Emerging Therapies for R/R DLBCL
July 15th 2020
CD19-Directed Therapies for Treatment of R/R DLBCL
July 15th 2020
ASCO 2020 Data: CAR T in R/R DLBCL
July 15th 2020
Treatment of R/R DLBCL: CD19-Directed Therapy vs CAR T
July 15th 2020
Standard of Care for Treatment of DLBCL
July 15th 2020

Trending on OncLive

FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer

FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer

VIR-5500 Receives FDA Fast Track Designation in mCRPC

September Roundup of FDA Approvals in Oncology: 8 Decisions to Know

Individualized Neoantigen Vaccine Elicits Durable T-Cell Responses in Resected HPV– HNSCC